Literature DB >> 18409065

Rearranged ent-kauranes from the stems of Tricalysia dubia and their biological activities.

Naoko Tamaki1, Katsuyoshi Matsunami, Hideaki Otsuka, Takakazu Shinzato, Mitsunori Aramoto, Yoshio Takeda.   

Abstract

From the EtOAc-soluble fraction of an MeOH extract of the stems of Tricalysia dubia, two new rearranged ent-kaurane derivatives, named tricalysiolides H and I, were isolated, together with five known rearranged ent-kauranes, i.e. tricalysiolides A-E, stigmast-4-en-6beta-ol-3-one, (+)-pinoresinol, scopoletin and syringaldehyde. Their structures were elucidated from spectroscopic evidence, and their cytotoxicity toward KB cells and P-gp inhibitory activity were assayed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18409065     DOI: 10.1007/s11418-008-0248-x

Source DB:  PubMed          Journal:  J Nat Med        ISSN: 1340-3443            Impact factor:   2.343


  9 in total

1.  Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease.

Authors:  N I Nissen; H H Hansen; H Pedersen; I Stroyer; P Dombernowsky; M Hessellund
Journal:  Cancer Chemother Rep       Date:  1975 Sep-Oct

2.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.

Authors:  R L Juliano; V Ling
Journal:  Biochim Biophys Acta       Date:  1976-11-11

Review 3.  P-glycoprotein multidrug resistance and cancer.

Authors:  I Bosch; J Croop
Journal:  Biochim Biophys Acta       Date:  1996-10-09

4.  Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors.

Authors:  H Stähelin
Journal:  Eur J Cancer       Date:  1973-03       Impact factor: 9.162

5.  Tricalysiosides H-O: Ent-kaurane glucosides from the leaves of Tricalysia dubia.

Authors:  Dong-Hui He; Katsuyoshi Matsunami; Hideaki Otsuka; Takakazu Shinzato; Mitsunori Aramoto; Masahiko Bando; Yoshio Takeda
Journal:  Phytochemistry       Date:  2005-11-03       Impact factor: 4.072

6.  Tricalysiosides A-G: rearranged ent-kauranoid glycosides from the leaves of Tricalysia dubia.

Authors:  Dong-Hui He; Hideaki Otsuka; Eiji Hirata; Takakazu Shinzato; Masahiko Bando; Yoshio Takeda
Journal:  J Nat Prod       Date:  2002-05       Impact factor: 4.050

7.  Biotransformation of pinoresinol diglucoside to mammalian lignans by human intestinal microflora, and isolation of Enterococcus faecalis strain PDG-1 responsible for the transformation of (+)-pinoresinol to (+)-lariciresinol.

Authors:  Li-Hua Xie; Teruaki Akao; Kenjiro Hamasaki; Takeshi Deyama; Masao Hattori
Journal:  Chem Pharm Bull (Tokyo)       Date:  2003-05       Impact factor: 1.645

Review 8.  Etoposide (VP-16-213).

Authors:  B F Issell; S T Crooke
Journal:  Cancer Treat Rev       Date:  1979-06       Impact factor: 12.111

9.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

  9 in total
  3 in total

1.  ent-Kaurane glycosides from Tricalysia okelensis.

Authors:  Wen-Hui Xu; Melissa Ruth Jacob; Ameeta Kishore Agarwal; Alice Mae Clark; Zong-Suo Liang; Xing-Cong Li
Journal:  Chem Pharm Bull (Tokyo)       Date:  2010-02       Impact factor: 1.645

2.  Mechanism Underlying the Reversal of Drug Resistance in P-Glycoprotein-Expressing Leukemia Cells by Pinoresinol and the Study of a Derivative.

Authors:  María L González; D Mariano A Vera; Jerónimo Laiolo; Mariana B Joray; Mariana Maccioni; Sara M Palacios; Gabriela Molina; Priscila A Lanza; Samanta Gancedo; Vivian Rumjanek; María C Carpinella
Journal:  Front Pharmacol       Date:  2017-04-25       Impact factor: 5.810

Review 3.  Potential Herb-Drug Interactions in the Management of Age-Related Cognitive Dysfunction.

Authors:  Maria D Auxtero; Susana Chalante; Mário R Abade; Rui Jorge; Ana I Fernandes
Journal:  Pharmaceutics       Date:  2021-01-19       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.